Literature DB >> 28609144

Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection.

Dan Zhang1, Lihua Fu2, Leilei Wang3, Lin Lin1, Lihong Yu1, Lijun Zhang1, Tao Shang3.   

Abstract

Immunomodulation by mesenchymal stem cells (MSCs) is potentially important for maintaining peripheral tolerance. Preeclampsia may be due to maternal immune rejection of the genetically foreign fetus. This study aimed to investigate the biological function of human umbilical cord-derived mesenchymal stem cells (HU-MSCs) for the treatment of angiotensin receptor agonistic autoantibody (AT1-AA)-induced hypertension during pregnancy. HU-MSCs were isolated, cultured, and labeled in vitro. AT1-AA and HU-MSCs were administered to pregnant rats. Green fluorescent protein (GFP)-positive HU-MSCs infused in vivo were identified by immunofluorescence. Systolic blood pressure (SBP) was evaluated. The effects of HU-MSCs on fetal weight, kidney burden, and spiral artery remodeling, as well as on the expression of tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), and heme oxygenase 1 (HO-1), were investigated. The SBP levels in the HU-MSC-treated pregnant hypertension rats decreased by gestational day 19. The reduction in fetal weight was largely ameliorated after HU-MSC treatment. Lesion burden in the kidney was attenuated and spiral artery remodeling was improved in HU-MSC-treated pregnant hypertension rats. However, green fluorescent protein (GFP)-labeled cells were sparingly observed in the kidney and placenta. Intravenous infusion of HU-MSCs into AT1-AA-induced rats significantly downregulated serum TNF-α levels and upregulated IL-10 levels, concomitant with increased placenta and mesometrial triangle (MT) HO-1 expression. Taken together, intravenous infusion of HU-MSCs ameliorates AT1-AA-induced pregnancy hypertension, intrauterine growth retardation, kidney impairment, and spiral artery remodeling impairment. Moreover, the potential benefits of HU-MSCs may be attributable to both an interference with the pathogenic immune response and a paracrine cytoprotective action.

Entities:  

Keywords:  Angiotensin receptor agonistic autoantibody; mesenchymal stem cells; preeclampsia; spiral artery remodeling

Mesh:

Substances:

Year:  2017        PMID: 28609144     DOI: 10.1080/10641955.2017.1329429

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  13 in total

Review 1.  Drug transport across the human placenta: review of placenta-on-a-chip and previous approaches.

Authors:  Rajeendra L Pemathilaka; David E Reynolds; Nicole N Hashemi
Journal:  Interface Focus       Date:  2019-08-16       Impact factor: 3.906

Review 2.  Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.

Authors:  Anjali Sharma; Nirnath Sah; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2021-08-26       Impact factor: 17.873

3.  Preeclamptic Women Have Decreased Circulating IL-10 (Interleukin-10) Values at the Time of Preeclampsia Diagnosis: Systematic Review and Meta-Analysis.

Authors:  Meryl C Nath; Hajrunisa Cubro; Daniel J McCormick; Natasa M Milic; Vesna D Garovic
Journal:  Hypertension       Date:  2020-10-26       Impact factor: 10.190

Review 4.  The Role of Interleukin-10 in the Pathophysiology of Preeclampsia.

Authors:  Hajrunisa Cubro; Sonu Kashyap; Meryl C Nath; Allan W Ackerman; Vesna D Garovic
Journal:  Curr Hypertens Rep       Date:  2018-04-30       Impact factor: 5.369

Review 5.  [Research progress in mesenchymal stem cells modified by Heme oxygenase 1].

Authors:  Dong Sun; Hongli Song; Zhongyang Shen
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-07-15

Review 6.  Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.

Authors:  S Suvakov; C Richards; V Nikolic; T Simic; K McGrath; A Krasnodembskaya; L McClements
Journal:  Curr Hypertens Rep       Date:  2020-04-14       Impact factor: 5.369

Review 7.  Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.

Authors:  Manoj Kumar Jena; Neeta Raj Sharma; Matthew Petitt; Devika Maulik; Nihar Ranjan Nayak
Journal:  Biomolecules       Date:  2020-06-24

8.  Potential biological therapies for severe preeclampsia: a systematic review and meta-analysis.

Authors:  Sophia Grimes; Kira Bombay; Andrea Lanes; Mark Walker; Daniel J Corsi
Journal:  BMC Pregnancy Childbirth       Date:  2019-05-09       Impact factor: 3.007

9.  Effect of Placenta-Derived Mesenchymal Stromal Cells Conditioned Media on an LPS-Induced Mouse Model of Preeclampsia.

Authors:  Anna Maria Nuzzo; Laura Moretti; Paolo Mele; Tullia Todros; Carola Eva; Alessandro Rolfo
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

Review 10.  Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility.

Authors:  Sahar Esfandyari; Rishi Man Chugh; Hang-Soo Park; Elie Hobeika; Mara Ulin; Ayman Al-Hendy
Journal:  Cells       Date:  2020-10-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.